| Accession |
PRJCA017352 |
| Title |
A phase II randomized clinical study of atrilizumab and Trastuzumab in combination with Capecitabine and Oxaliplatin (XELOX) in patients with HER2-positive gastric cancer or GEJ |
| Relevance |
Medical |
| Data types |
Her2 Copy number of ctDNA no sequencing involved
|
| Organisms |
Homo sapiens
|
| Description |
This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in patients eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ. The study will enroll approximately 42 patients in China. |
| Sample scope |
Multiisolate |
| Release date |
2023-06-02 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Roche/Genentech
|
|
na
|
|
|
|
| Submitter |
lin
shen (linshenpku@163.com)
|
| Organization |
Beijing Cancer Hospital |
| Submission date |
2023-05-30 |
